Company intelligence / Profile preview

MSTC Development

Ownership: Private
Development stage: Other

Overview

MSTC Development is a biotechnology company focused on the development of novel small molecule inhibitors targeting the Hippo signaling pathway. The company specifically targets MST1 and MST2 kinases to modulate tissue regeneration and cellular proliferation. Their primary therapeutic focus includes the treatment of chronic liver diseases and potential applications in oncology where Hippo pathway dysregulation is a key driver. By inhibiting MST1/2, the company aims to promote the activation of YAP/TAZ, thereby stimulating endogenous tissue repair mechanisms. MSTC Development is currently advancing its lead programs through pre-clinical validation.

Therapeutic areas: OncologyOtherGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MSTC Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSTC Development.

Explore the full profile